SC
RNAZ icon

SouthState Corp’s TransCode Therapeutics RNAZ Stock Holding History

SouthState Corp’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-482
Closed -$3.76K – 1563
2025
Q2 		$3.76K Sell
482
-161
-25% -$1.49K ﹤0.01% 974
2025
Q1 		$8.91K Buy
+643
New +$82.4K ﹤0.01% 856

Other funds holding RNAZ

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SouthState Corp's RNAZ Position: Q3 2025 in Review

SouthState Corp sold out of TransCode Therapeutics (RNAZ) in Q3 2025, closing a stake of 482 shares — an estimated $3.76K sold.

SouthState Corp first reported a position in RNAZ in Q1 2025 and held it in 2 quarters. The position peaked at $8.91K in Q1 2025. 8 funds tracked by Wall St. Rank hold RNAZ as of Q3 2025.

  • SouthState Corp reported no remaining TransCode Therapeutics position as of Q3 2025 after selling out during the quarter.
  • SouthState Corp sold 482 TransCode Therapeutics shares in Q3 2025, an estimated $3.76K.
  • SouthState Corp first reported a position in TransCode Therapeutics in Q1 2025 and held it in 2 quarters.
  • SouthState Corp's TransCode Therapeutics position peaked at $8.91K in Q1 2025.
  • 8 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q3 2025.

Based on SouthState Corp's 13F filing for Q3 2025, filed 5 Nov 2025.